Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

Showing 51 to 100 of 291

TitleReference numberPublishedLast updated
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Relugolix for treating hormone-sensitive prostate cancerTA995
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)TA994
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapyTA992
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerHTG719
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancerHTG714
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Ovarian cancer: identifying and managing familial and genetic riskNG241
Lung cancer: diagnosis and managementNG122
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Ovarian cancer: recognition and initial managementCG122
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary careHTG690
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908
Irreversible electroporation for treating prostate cancerHTG688
Oesophago-gastric cancer: assessment and management in adultsNG83
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancerTA903
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancerHTG681
Transperineal biopsy for diagnosing prostate cancerHTG680
MRI fusion biopsy systems for diagnosing prostate cancerHTG678
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Focal therapy using high-intensity focused ultrasound for localised prostate cancerHTG667
Maximal cytoreductive surgery for advanced ovarian cancerHTG668
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Regorafenib for previously treated metastatic colorectal cancerTA866
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerHTG659
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Thyroid cancer: assessment and managementNG230
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerHTG642

Results per page

  1. 10
  2. 25
  3. 50
  4. All